FDA Approves Genentech’s Alecensa For ALK-positive Early-Stage Lung Cancer
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Genentech, a member of the Roche Group (RHHBY), said that the U.S. Food and Drug Administration has approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer or
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2150466569-52a85a86f8bf44fb8d2dee9c1f497c40.jpg "Next Fed Meeting: When It Is in June and What To Expect")